期刊文献+

去甲万古霉素群体药代动力学与药效学优化研究

Study on the Pharmacokinetics and Pharmacodynamics of Vancomycin in Population
下载PDF
导出
摘要 目的研究去甲万古霉素群体药代动力学指标差异,对患者进行药效学优化。方法选取2015年1月至2015年12月268例感染患者,将其按照年龄分为中青年组和老年组,每组各134例,采用群体药代动力学和药效学优化公式进行计算,分析患者上述指标差异。结果青年组与老年组的群体药代动力学各项指标差异明显具有统计学意义(P<0.05)。结论感染患者通过去甲万古霉素药物治疗疗效确切,对革兰阳性菌的杀灭作用明显,采用群体药代动力学和药效学研究后发现,AUC24/MIC能够作为去甲万古霉素的应用指标,并以此指导临床用药效果显著,值得临床应用推广。 Objective To study the difference of the pharmacokinetic parameters between the groups and to optimize the pharmacodynamics of the patients. Methods In our hospital from January 2015 to December 2015 were 268 cases,according to the divided into young group and the old age group, 134 cases in each group, the pharmacokinetics and pharmacodynamics of group medicine formula optimization,analysis of differences between patients with the above indexes. Results There were significant differences between the young group and the old group in the pharmacokinetic parameters of each group ( P 〈 0. 05). Conclusion The curative effect of vancomycin to patients infected by drug treatment is effective, obvious killing effect on Gram positive bacteria, the pharmacokinetic and pharmacodynamic study of population pharmacokinetics showed that AUC24/MIC can use as indicators of norvancomycin,and to guide the clinical medication effect is significant,worthy of clinical application.
作者 王芷
出处 《广东微量元素科学》 CAS 2017年第3期19-22,共4页 Trace Elements Science
关键词 感染患者 去甲万古霉素 群体药代动力学 药效学 infected patients vancomycin population pharmacokinetics pharmacodynamics
  • 相关文献

参考文献5

二级参考文献148

  • 1曹靖.万古霉素在儿童病人中的用药分析[J].医学临床研究,2006,23(11):1754-1755. 被引量:4
  • 2World health Organization. Children : reducing mortality [EB/ OL]. (2016-01) [2016-07-22]. http://www.who.int/mediacen- tre/factsheets/fs 178/en/.
  • 3Shirkey I-I. Therapeutic orphans [J]. J Pediatr, 1968, 72( 1 ) :119-120.
  • 4Choonara I. Unlicensed and off-label drug use in children : im- plications for safety [J]. Expert Opin Drug Saf, 2004, 3(2) : 81-83.
  • 5Pandolfini C, Bonati M. A literature review on off-label drug use in children [J]. Eur J Pediatr, 2005,164(9):552-558.
  • 6Bazzano AT, Mangione-Smith R, Sehonlau M, et al. Off-label preseribing to children in the United States outpatient setting [J]. Acad Pediatr, 2009, 9(2) : 81-88.
  • 7Bartelink IH, Rademaker CM, Schobbcn AF, et al. Guide- lines on paediatric dosing on the basis of developmental physi- ology and pharmacokinetie considerations [J ]. Clin Pharmaeo- kinet, 2006, 45 ( 11 ), 1077-1097.
  • 8De Cock RF, Piana C, Krekels EH, et al. The role of popula- tion PK-PD modelling in paediatric clinical research [J]. Eur J Clin Pharmacol, 2011, 67 (Suppl 1): 5-16.
  • 9Gazarian M. Delivering better medicines to children: need for better integration between the science, the policy, and the practice [J]. Paediatr Drugs, 2009, 11 ( 1 ) :41-44.
  • 10Holford NH. A size standard for pharmacokinetics [J]. Clin Pharmacokinet, 1996, 30(5):329-332.

共引文献55

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部